SENATE FLOOR VERSION
March 1, 2023

COMMITTEE SUBSTITUTE
FOR
SENATE BILL NO. 711

By: Rosino of the Senate
and
Boatman of the House

[ substance abuse services - emergency opioid antagonists - education program - codification - effective date ]

BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

SECTION 1. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 2-401.1 of Title 43A, unless there is created a duplication in numbering, reads as follows:

A. As used in this section, “emergency opioid antagonist” means a drug including but not limited to naloxone that blocks the effects of opioids and that is approved by the United States Food and Drug Administration for the treatment of an opioid overdose.

B. Subject to allocation of federal funding for the purchase of emergency opioid antagonists, the Department of Mental Health and Substance Abuse Services shall provide emergency opioid antagonists
C. The Department of Mental Health and Substance Abuse Services shall prepare and provide an opioid overdose education program to the Department of Corrections and to county jails for the purpose of implementing Section 2 of this act. The education program shall:

1. Conform to guidelines of the Substance Abuse and Mental Health Services Administration for opioid overdose education;

2. Explain the causes of an opioid overdose;

3. Instruct when and how to administer in accordance with medical best practices:
   a. life-saving rescue techniques, and
   b. an emergency opioid antagonist;

4. Explain how to contact appropriate emergency medical services; and

5. Provide information on how to access emergency opioid antagonists.

SECTION 2. AMENDATORY 57 O.S. 2021, Section 4.1, is amended to read as follows:

Section 4.1. A. In addition to other medical and health care services required by a jail facility as may be provided by rule by the State Department of Health, the person responsible for administration for a jail shall administer medications according to the following:
1. Prescription medications shall be provided to the prisoner as directed by a physician or designated medical authority. The prisoner shall be observed to ensure the prisoner takes the medication. The physician or designated medical authority shall be particularly aware through his or her training of the impact of opiate or methadone withdrawal symptoms that may occur in regard to the mental and physical health of the prisoner. The physician or medical authority shall prescribe and administer appropriate medications to the prisoner pursuant to Section 5-204 of Title 43A of the Oklahoma Statutes as the medical authority deems appropriate to address those symptoms. Neither prescription nor over-the-counter medications shall be kept by a prisoner in a cell with the exception of prescribed nitroglycerin tablets and prescription inhalers. Over-the-counter medications shall not be administered without a physician’s approval unless using prepackaged medications;  

2. Medical reception information shall be recorded on a printed screening form approved by the physician or designated medical authority which shall include inquiry into:
   a. current illnesses and health problems including medications taken and any special health requirements,  
   b. behavioral observation, including state of consciousness and mental status,  
   c. body deformities and trauma markings such as bruises, lesions, jaundice, and ease of body movement,
d. condition of skin and visible body orifices, including infestations, and
e. disposition or referral of prisoners to qualified medical personnel on an emergency basis; and

3. For purposes of this section, “physician or other licensed medical personnel” means a psychiatrist, medical doctor, osteopathic physician, physician’s assistant, registered nurse, licensed practical nurse, emergency medical technician at the paramedical level or clinical nurse specialist.

B. 1. Subject to the provision of emergency opioid antagonists by the Department of Mental Health and Substance Abuse Services under Section 1 of this act:

a. the Department of Corrections, upon the discharge of an inmate from an institution within the Department who has been diagnosed with an opioid use disorder, regardless of whether that inmate has received treatment for the disorder, shall provide the inmate, as the inmate leaves the institution, with two doses of an emergency opioid antagonist, and

b. a county jail:

(1) upon the discharge of any person who is confined in the jail pursuant to a sentence who has been diagnosed with an opioid use disorder, regardless
of whether that person has received treatment for
the disorder, or

(2) upon the discharge of any person who is confined
in the jail for an offense related to possession
of an opioid drug other than:

(a) a person who is confined in the jail
    pursuant to a sentence, or
(b) a person who is being transferred to the
custody of the Department of Corrections,

shall provide the person, as the person leaves the
jail, with two doses of an emergency opioid
antagonist.

2. Notwithstanding the provision of emergency opioid
antagonists by the Department of Mental Health and Substance Abuse
Services as provided by Section 1 of this act, the Department of
Corrections and county jails may stock and provide emergency opioid
antagonists to inmates or persons upon discharge from the
institution or jail as described in paragraph 1 of this subsection.

3. Before the Department of Corrections or a county jail
provides an emergency opioid antagonist to an inmate or person as
described in paragraph 1 or 2 of this subsection, the Department of
Corrections or the jail shall ensure that the inmate or person is
provided with the opioid overdose education program provided by the
Department of Mental Health and Substance Abuse Services under Section 1 of this act.

4. Nothing in this subsection is intended to abrogate or supersede any existing authority of the Department of Corrections or a county jail to administer an emergency opioid antagonist to a person experiencing an opioid overdose.

SECTION 3. This act shall become effective November 1, 2023.